CN106236741A - 用于治疗异常肾上腺皮质细胞疾病的化合物和方法 - Google Patents

用于治疗异常肾上腺皮质细胞疾病的化合物和方法 Download PDF

Info

Publication number
CN106236741A
CN106236741A CN201610595176.5A CN201610595176A CN106236741A CN 106236741 A CN106236741 A CN 106236741A CN 201610595176 A CN201610595176 A CN 201610595176A CN 106236741 A CN106236741 A CN 106236741A
Authority
CN
China
Prior art keywords
patient
phenyl
atr
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610595176.5A
Other languages
English (en)
Chinese (zh)
Inventor
加里·哈默
汤姆·凯尔波拉
拉伊利·凯尔波拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Milunduo Treatment Co
University of Michigan System
Original Assignee
Milunduo Treatment Co
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milunduo Treatment Co, University of Michigan System filed Critical Milunduo Treatment Co
Publication of CN106236741A publication Critical patent/CN106236741A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201610595176.5A 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法 Pending CN106236741A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614269P 2012-03-22 2012-03-22
US61/614,269 2012-03-22
CN201380015269.0A CN104302283B (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380015269.0A Division CN104302283B (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Publications (1)

Publication Number Publication Date
CN106236741A true CN106236741A (zh) 2016-12-21

Family

ID=48014328

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610595176.5A Pending CN106236741A (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法
CN201380015269.0A Active CN104302283B (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380015269.0A Active CN104302283B (zh) 2012-03-22 2013-03-13 用于治疗异常肾上腺皮质细胞疾病的化合物和方法

Country Status (12)

Country Link
US (5) US9107883B2 (enExample)
EP (1) EP2838523A1 (enExample)
JP (2) JP6234987B2 (enExample)
CN (2) CN106236741A (enExample)
AU (2) AU2013235535B2 (enExample)
BR (1) BR112014023517B1 (enExample)
CA (1) CA2867668A1 (enExample)
HK (1) HK1206607A1 (enExample)
IN (1) IN2014DN08604A (enExample)
MX (1) MX355129B (enExample)
NZ (1) NZ630828A (enExample)
WO (1) WO2013142214A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2748238B2 (ja) 1994-12-20 1998-05-06 新興機械工業株式会社 ばね製造装置の足起こし装置
BR112014023517B1 (pt) * 2012-03-22 2020-12-01 The Regents Of The University Of Michigan Usos de cloridrato de n-(2,6-bis(1-metiletil)fenil)-n-((1-(4-(dimetilamino)fenil)ciclopentil) metil)ureia para tratar distúrbios das células do córtex adrenal anormais
WO2015048543A1 (en) * 2013-09-26 2015-04-02 Atterocor, Inc. Treating disorders associated with aberrant adrenocortical cell behavior
MX2017003916A (es) * 2014-09-26 2017-06-30 Millendo Therapeutics Inc Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.
WO2016164476A2 (en) * 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
WO2017011302A1 (en) * 2015-07-10 2017-01-19 Millendo Therapeutics, Inc. Enhanced bioavailability of n-(2,6-bis(1-methylethyl) phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl) methyl)urea hydrochloride
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US10231983B1 (en) 2018-08-22 2019-03-19 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US11202787B2 (en) 2018-07-02 2021-12-21 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US10780097B2 (en) 2018-07-02 2020-09-22 Corcept Therapeutics, Inc. Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
JP7784121B2 (ja) * 2019-06-11 2025-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を治療するための組成物および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
BRPI0719941A2 (pt) * 2006-12-06 2014-04-22 Smithkline Beecham Corp Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
BR112014023517B1 (pt) * 2012-03-22 2020-12-01 The Regents Of The University Of Michigan Usos de cloridrato de n-(2,6-bis(1-metiletil)fenil)-n-((1-(4-(dimetilamino)fenil)ciclopentil) metil)ureia para tratar distúrbios das células do córtex adrenal anormais

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARK A.DOMINICK等: "Morphogensis of a Zone-Specific Adrenocortical Cytotoxicity in Guinea Pigs Administered PD 12301-2, an Inhibitor of Acyl-CoA: Cholesterol Acyltransferase", 《TOXICOLOGIC PATHOLOGY》 *
江绍基: "肝脏的良性肿瘤", 《临床肝胆系病学》 *
颜廷仁等: "酰基辅酶A-胆固醇酰基转移酶抑制剂", 《国外医学药学分册》 *

Also Published As

Publication number Publication date
MX2014011188A (es) 2015-03-06
EP2838523A1 (en) 2015-02-25
AU2013235535A1 (en) 2014-10-09
JP2017160275A (ja) 2017-09-14
JP6317016B2 (ja) 2018-04-25
US20180256524A1 (en) 2018-09-13
MX355129B (es) 2018-04-06
CN104302283B (zh) 2016-08-24
AU2017261632A1 (en) 2017-12-07
CA2867668A1 (en) 2013-09-26
US20160367507A1 (en) 2016-12-22
AU2013235535B2 (en) 2017-09-21
US20220160662A1 (en) 2022-05-26
US20130267550A1 (en) 2013-10-10
US9107883B2 (en) 2015-08-18
BR112014023517B1 (pt) 2020-12-01
JP2015510933A (ja) 2015-04-13
NZ630828A (en) 2016-10-28
JP6234987B2 (ja) 2017-11-22
US20160008302A1 (en) 2016-01-14
CN104302283A (zh) 2015-01-21
HK1206607A1 (en) 2016-01-15
IN2014DN08604A (enExample) 2015-05-22
WO2013142214A1 (en) 2013-09-26
US9877937B2 (en) 2018-01-30
US9446010B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
CN104302283B (zh) 用于治疗异常肾上腺皮质细胞疾病的化合物和方法
TWI377062B (en) Pharmaceutical compositions and dosage forms of thalidomide
TWI289449B (en) Compositions and methods for the treatment of cancer
TWI308913B (en) Use of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline in treatment and management of brain cancer
TWI542349B (zh) 利用３－（５－胺基－２－甲基－４－氧基－４ｈ－喹唑啉－３－基）－六氫吡啶－２，６－二酮治療癌症之方法
JP6727237B2 (ja) 血液がん及び固形腫瘍の治療のための併用療法
US20020128228A1 (en) Compositions and methods for the treatment of cancer
ES2940302T3 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
EP3938368B1 (en) Compound form having enhanced bioavailability and formulations thereof
US20160279160A1 (en) Compositions comprising spicamycin derivatives and methods of use thereof
TW201642857A (zh) 以組合療法治療肝細胞癌
TWI870704B (zh) 治療表達pd-l1之癌症的方法
HK1230524A (en) Compounds and methods for treating aberrant adrenocartical cell disorders
HK1230524A1 (en) Compounds and methods for treating aberrant adrenocartical cell disorders
US20240216465A1 (en) Method for treating refractory brain tumor
TW202428876A (zh) 治療難治型腦瘤之方法
WO2008036954A1 (en) Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
HK40065292B (en) Compound form having enhanced bioavailability and formulations thereof
WO2008073304A2 (en) Cancer treatment methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230524

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161221

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1230524

Country of ref document: HK